|
Kenvue used to be a part of Johnson & Johnson. J&J announced in
late 2021 that it was splitting its consumer health division
from the pharmaceutical and medical device divisions in a bid to
make each more nimble.
Kenvue said Monday that board member Kirk Perry will serve as
interim CEO, effective immediately. Perry has served as a
director since December and most recently served as CEO of
Circana, a provider of market research. He spent more than 20
years at Procter & Gamble in various roles.
Kenvue also said that it is continuing to work with its
strategic review committee to explore options for the company.
“The Board’s strategic review is underway, and we are
considering a broad range of potential alternatives, including
ways to simplify the Company’s portfolio and how it operates,"
Chair Larry Merlo said in a statement.
Kenvue provided some preliminary results for its fiscal second
quarter. The company anticipates adjusted earnings in a range of
28 cents to 29 cents per share. Analysts polled by FactSet
expect earnings of 28 cents per share.
Kenvue will report its full quarterly results on Aug. 7 and said
that it will revise its full-year outlook on that date.
Shares rose more than 4% before the market open.
All contents © copyright 2025 Associated Press. All rights reserved
|
|
